Caribou to Present 84-Patient Vispa-cel Durability, 48-Patient CB-011 Follow-Up at EHA
Caribou Biosciences will present long-term durability data for vispa-cel from its ANTLER phase 1 trial at the EHA meeting June 12, following treatment of 84 patients and identification of 80×10^6 CAR-T cells as RP2D. A second presentation on June 14 covers extended follow-up in 48-patient CaMMouflage phase 1 CB-011 trial.
1. EHA Abstract Acceptance
Caribou Biosciences secured acceptance of two abstracts for oral presentation at the 2026 European Hematology Association Annual Meeting in Stockholm from June 11-14. The first session (Abstract S236) on June 12 will highlight vispa-cel durability, and the second (Abstract S201) on June 14 will detail CB-011 follow-up.
2. Vispa-cel ANTLER Phase 1 Data
The ANTLER phase 1 trial evaluated vispa-cel, an allogeneic anti-CD19 CAR-T therapy with PD-1 knockout, in 84 patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Doses of 40×10^6, 80×10^6 and 120×10^6 CAR-T cells were tested, with 80×10^6 cells selected as the recommended phase 2 dose.
3. CB-011 CaMMouflage Phase 1 Follow-Up
The CaMMouflage trial is assessing CB-011, an allogeneic anti-BCMA CAR-T therapy with immune cloaking, in 48 relapsed/refractory multiple myeloma patients across dose levels from 50×10^6 to 800×10^6 cells. Extended follow-up from the dose escalation cohort will be presented to evaluate safety and efficacy outcomes.